ViroGates Press Release

Fri May 18 2018

ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.

Following extensive clinical validation and clinical utility studies in more than 300,000 patients, suPARnostic® is now being tested in numerous clinical emergency departments across Europe.

“Increased health care spending is a tremendous challenge for healthcare systems worldwide.

ViroGates helps clinicians in their daily decision making in connection with admission or discharge of patients. This way, the healthcare systems can allocate resources more effectively” says Jakob Knudsen, CEO, ViroGates.

The company has appointed Dr. Thomas Krarup as VP Sales & Marketing to lead the international clinical rollout.

ViroGates is currently evaluating different options for funding of its commercial execution.

For more information, please see Press Release here

For yderligere information, se Pressemeddelelsen her

Plese find the Danish article in MedWatch “Biotekselskab fra Birkerød ruller blodtest ud på europæiske hospitaler” here

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates